Trials / Completed
CompletedNCT02157636
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Constellation Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPI-0610 |
Timeline
- Start date
- 2014-07-15
- Primary completion
- 2016-11-08
- Completion
- 2016-11-08
- First posted
- 2014-06-06
- Last updated
- 2024-04-18
Source: ClinicalTrials.gov record NCT02157636. Inclusion in this directory is not an endorsement.